A multi-activity synergistic complex composition comprising ergothioneine-pqq- urolithin a

Abstract

This invention discloses a multi-active synergistic compound composition comprising ergothioneine-PQQ-urolithin A, belonging to the field of functional food and pharmaceutical technology. The active ingredients of this composition consist only of ergothioneine, pyrrolquinone or their pharmaceutically acceptable salts, and urolithin A, in parts by weight of 5-30 parts, 1-10 parts, and 5-25 parts, respectively. Ergothioneine accumulates in mitochondria via the OCTN1 transporter to scavenge reactive oxygen species; pyrrolquinone activates the PGC-1α pathway to promote mitochondrial biogenesis; and urolithin A induces mitophagy through the PINK1 / Parkin pathway to clear damaged mitochondria. These three components form a synergistic regulatory effect throughout the mitochondrial life cycle. This composition can improve mitochondrial function and can be used to prepare anti-fatigue and anti-aging related products.

Description

Technical Field

[0001] This invention belongs to the field of functional food and pharmaceutical technology, and specifically relates to a multi-active synergistic compound composition containing ergothioneine-PQQ-urolithin A. Background Technology

[0002] Mitochondria are key organelles in eukaryotic cells, responsible for oxidative phosphorylation and the synthesis of adenosine triphosphate (ATP), earning them the title of the cell's "energy factories." The functional state of mitochondria directly affects cellular energy supply, reactive oxygen species metabolism, calcium homeostasis regulation, and the process of apoptosis. With age or under pathophysiological conditions such as oxidative stress, exercise fatigue, and metabolic disorders, mitochondrial DNA mutations accumulate, respiratory chain efficiency declines, and the clearance of damaged mitochondria is impaired, leading to insufficient cellular energy and exacerbated oxidative damage, which in turn triggers fatigue, aging, and various degenerative diseases. Therefore, regulating mitochondrial quality and maintaining mitochondrial functional homeostasis through exogenous active ingredients is an important strategy for combating fatigue, delaying aging, and improving metabolic health.

[0003] Currently, several natural active ingredients are known to act on mitochondria at different stages. Ergothioneine (EGT) is a natural sulfur-containing amino acid with strong antioxidant activity. Its unique feature lies in the presence of a specific transporter on the cell membrane, OCTN1 (SLC22A4), which actively transports and accumulates ergothioneine in organelles such as mitochondria. In the mitochondrial matrix, it directly scavenge superoxide anions and hydroxyl radicals, protecting the mitochondrial membrane and respiratory chain complexes from oxidative damage. Pyrroloquinoline quinone (PQQ) is a redox cofactor that can activate the peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) signaling pathway, upregulating the expression of mitochondrial transcription factor A (TFAM), thereby promoting mitochondrial biogenesis, increasing mitochondrial numbers, and enhancing respiratory chain function. Urolithin A (UA) is a natural small molecule produced by the metabolism of ellagic tannin and ellagic acid by gut microbiota. It can activate the PINK1 / Parkin-mediated mitophagy pathway, selectively recognize and clear damaged and aging mitochondria, and make room and resources for new mitochondria.

[0004] In the prior art, products and compositions containing the above-mentioned ingredients have been reported. For example, some anti-aging compositions use a mixture of multiple ingredients such as ergothioneine, PQQ, urolithin A, calcium α-ketoglutarate, fisetin, rhodioloside, spermidine, and apple stem cell extract, with the number of ingredients reaching seven or eight or more; other compositions use a binary combination of PQQ and ergothioneine for whitening and anti-aging, or a ternary combination of urolithin, urolithin A, and ergothioneine for skin care. However, the aforementioned existing technologies have the following shortcomings: First, the target and mechanism of action of each active ingredient in the multi-component complex lack targeted synergistic design. Ergothioneine, PQQ, and urolithin A act on three different links: mitochondrial protection, mitochondrial regeneration, and mitophagy, respectively, but they are submerged among numerous ingredients in the complex, and the ratio and synergistic effect among the three have not been identified and optimized. Second, existing binary or ternary combinations either lack the autophagy clearance link of urolithin A or are designed for topical skin whitening without targeting the closed-loop cycle of mitochondrial quality regulation. Third, existing technologies do not disclose pure ternary compositions consisting only of three active ingredients: ergothioneine, PQQ, and urolithin A, with their mass ratio optimized to achieve synergistic effects of mitochondrial protection, regeneration, and clearance.

[0005] Therefore, it is necessary to develop a multi-active compound composition with simplified ingredients, clear targets, and synergistic ratios, so that ergothioneine, PQQ, and urolithin A can form a closed-loop regulation at the mitochondrial level, thereby more effectively improving mitochondrial function. Summary of the Invention

[0006] In view of this, the present invention provides a multi-active synergistic compound composition containing ergothioneine-PQQ-urolithin A to solve or alleviate one of the technical problems existing in the prior art, and at least provides an advantageous alternative.

[0007] The technical solution of this invention is implemented as follows: This invention provides a multi-active synergistic compound composition, wherein the active ingredients of the composition consist only of ergothioneine, pyrroloquinoline quinone or a pharmaceutically acceptable salt thereof, and urolithin A; by weight, the ergothioneine is 5-30 parts, the pyrroloquinoline quinone or a pharmaceutically acceptable salt thereof is 1-10 parts, and the urolithin A is 5-25 parts.

[0008] Further, by weight, the ergothione is 10-25 parts, the pyrroloquinoline quinone or its pharmaceutically acceptable salt is 2-8 parts, and the urolithin A is 8-20 parts.

[0009] Furthermore, by weight, the ergothione is 12 to 20 parts, the pyrroloquinoline quinone or its pharmaceutically acceptable salt is 3 to 6 parts, and the urolithin A is 10 to 16 parts.

[0010] In one specific embodiment, the pharmaceutically acceptable salt of the pyrroloquinoline quinone is the disodium salt of pyrroloquinoline quinone.

[0011] In one specific embodiment, the ergothioneine is L-ergothioneine.

[0012] In one embodiment, the composition further comprises pharmaceutically or food-grade excipients, including at least one of fillers, binders, disintegrants, lubricants, flow aids, flavoring agents, and preservatives. The filler may be selected from at least one of microcrystalline cellulose, lactose, mannitol, starch, and dicalcium phosphate; the binder may be selected from at least one of polyvinylpyrrolidone, hydroxypropyl methylcellulose, and starch paste; the disintegrant may be selected from at least one of crospovidone, sodium carboxymethyl starch, and low-substituted hydroxypropyl cellulose; and the lubricant may be selected from at least one of magnesium stearate, stearic acid, and talc.

[0013] In one specific embodiment, the dosage form of the composition is an oral preparation, which includes tablets, hard capsules, granules, powders, or oral liquids.

[0014] This invention also provides a method for preparing the above-mentioned multi-active synergistic compound composition, comprising the following steps: weighing ergothioneine, pyrroloquinoline quinone or their pharmaceutically acceptable salts, and urolithin A according to predetermined mass parts; placing the three in a mixing device and mixing for 15-40 minutes at a speed of 20-60 rpm under inert gas protection to obtain an active ingredient premix; mixing the active ingredient premix with pharmaceutically or food-acceptable excipients until uniform, and then granulating or directly filling to obtain the multi-active synergistic compound composition. The inert gas is nitrogen or argon, and the relative humidity of the environment is controlled not to exceed 40% during the mixing process to reduce the oxidation and hygroscopic degradation of the active ingredients.

[0015] This invention also provides the application of the above-mentioned multi-active synergistic compound in the preparation of products that improve mitochondrial function. The improvement of mitochondrial function includes at least one of increasing mitochondrial membrane potential, increasing intracellular ATP levels, promoting mitochondrial biogenesis, and inducing mitophagy. The product is a health food, a food for special medical purposes, or a dietary supplement.

[0016] The embodiments of the present invention have the following advantages due to the adoption of the above technical solutions: First, the active ingredients of the composition of this invention consist of only three substances: ergothioneine, PQQ, and urolithin A. This concise composition avoids potential interference between components in multi-component complex formulations. The three components act on three key aspects of mitochondrial quality regulation: ergothioneine accumulates in mitochondria via the OCTN1 transporter, scavenging reactive oxygen species in the mitochondrial matrix and protecting the membrane structure and respiratory chain function of existing healthy mitochondria; PQQ activates the PGC-1α / TFAM pathway, promoting mitochondrial biogenesis and increasing the number and function of newly formed mitochondria; urolithin A activates the PINK1 / Parkin pathway, inducing mitophagy and selectively clearing damaged and aging mitochondria. These three components form a closed-loop regulatory mechanism for the entire mitochondrial lifecycle: "antioxidant protection—biogenesis—autophagy clearance," which can more comprehensively and effectively improve mitochondrial function.

[0017] Second, this invention optimizes the synergistic effect of the three components within a specific mass ratio range. When the mass ratio of ergothioneine, PQQ, and urolithin A is within the range of 5–30:1–10:5–25, the intensity of their effects on mitochondrial protection, regeneration, and clearance is balanced, avoiding regulatory imbalances caused by excessive amounts of any single component. For example, if the proportion of ergothioneine is too low, mitochondrial antioxidant protection is insufficient, and PQQ-promoted newly formed mitochondria lack protection and are susceptible to oxidative damage; if the proportion of urolithin A is too high, excessive activation of autophagy may clear normally functioning mitochondria. The specified proportion range of this invention maximizes the synergistic effect of the three components, which is beneficial for increasing mitochondrial membrane potential and intracellular ATP content.

[0018] Third, the preparation method of the present invention adopts a premixing process under inert gas protection and low humidity environment, which is beneficial to maintain the stability of active ingredients such as ergothioneine and PQQ that are sensitive to oxidation and humidity, reduce the loss of activity during the preparation process, and thus ensure the consistency of product efficacy.

[0019] Fourth, the composition of the present invention is an oral preparation, which is convenient to take and is suitable for preparing health foods, special medical purpose formula foods or dietary supplements related to improving mitochondrial function, anti-fatigue and delaying aging, and has good application prospects.

[0020] The above overview is for illustrative purposes only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments, and features described above, further aspects, embodiments, and features of the invention will become readily apparent from the accompanying drawings and the following detailed description. Attached Figure Description

[0021] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0022] Figure 1 This is a schematic diagram of the mitochondrial synergistic mechanism of the composition of the present invention; Figure 2 This is a schematic flowchart of the method for preparing the composition of the present invention; Figure 3 A bar chart comparing the mitochondrial membrane potential (JC-1 polymer / monomer fluorescence ratio) detection results of each group of cells in this invention; Figure 4 This is a bar chart comparing the results of intracellular ATP content detection in each group of the present invention. Figure 5 This is a bar chart comparing the swimming time of mice in different groups under load according to the present invention. Detailed Implementation

[0023] In the following description, only certain exemplary embodiments are briefly described. As those skilled in the art will recognize, the described embodiments can be modified in various ways without departing from the spirit or scope of the invention. Therefore, the drawings and description are considered to be exemplary in nature and not restrictive.

[0024] The embodiments of the present invention will now be described in detail with reference to the accompanying drawings.

[0025] The mitochondrial synergistic mechanism of the composition of the present invention is as follows: Figure 1 As shown: Ergothione enters the mitochondria via the OCTN1 transporter on the cell membrane, scavenging reactive oxygen species within the mitochondria and protecting existing healthy mitochondria; pyrroloquinoline quinone activates the PGC-1α signaling pathway, promoting mitochondrial biogenesis and generating new mitochondria; urolithin A activates the PINK1 / Parkin signaling pathway, forming mitophagosomes that encapsulate and eliminate damaged mitochondria. Ergothione, pyrroloquinoline quinone, and urolithin A form a closed-loop synergistic regulation of the entire mitochondrial lifecycle: "antioxidant protection—biogenesis—autophagy clearance."

[0026] The preparation method of the composition of the present invention is as follows: Figure 2 As shown: The three weighed active ingredients are put into the mixing equipment, and inert gas is introduced through the inert gas inlet for protection. After mixing, an active ingredient premix is ​​obtained. After adding excipients through the excipient inlet and mixing, it is sent to the granulation / filling unit for processing to obtain the finished product.

[0027] Example 1: Preparation of a multi-active synergistic compound composition (capsule)

[0028] Weigh out 15 parts by weight of L-ergothioneine, 5 parts by weight of disodium pyrroloquinoline quinone, and 12 parts by weight of urolithin A. Place the three active ingredients in a three-dimensional motion mixer, and purge the air inside the mixer with nitrogen through the inert gas inlet to control the oxygen content inside the mixer to be below 2%. Mix at a speed of 40 rpm for 25 minutes under nitrogen protection to obtain the premix of active ingredients.

[0029] Weigh out 40 parts of microcrystalline cellulose, 20 parts of lactose, 5 parts of crospovidone, and 1 part of magnesium stearate as excipients. Place the premixed active ingredients, microcrystalline cellulose, lactose, and crospovidone in a mixer and mix for 15 minutes. Finally, add magnesium stearate and mix for 3 minutes to obtain a total powder. Fill the total powder directly into No. 1 hard capsules, with each capsule containing 300 mg of the contents, thus obtaining the multi-active synergistic compound capsule formulation of this embodiment.

[0030] In this embodiment, the mass ratio of ergothioneine, disodium PQQ, and urolithin A is 15:5:12, which falls within the range of 5-30:1-10:5-25 defined in claim 1, and also within the range of 10-25:2-8:8-20 defined in claim 2 and 12-20:3-6:10-16 defined in claim 3.

[0031] Example 2: Preparation of a multi-active synergistic compound composition (tablets)

[0032] Weigh out 20 parts by weight of L-ergothioneine, 6 parts by weight of disodium pyrroloquinoline quinone, and 16 parts by weight of urolithin A. Place the three active ingredients in a trough mixer, purge with nitrogen for protection, and mix at 30 rpm for 30 minutes to obtain the active ingredient premix.

[0033] Weigh out 35 parts of microcrystalline cellulose, 15 parts of mannitol, 3 parts of polyvinylpyrrolidone K30, 4 parts of sodium carboxymethyl starch, and 1 part of magnesium stearate as excipients. Mix the premix of active ingredients with microcrystalline cellulose and mannitol evenly, add a 50% ethanol solution of polyvinylpyrrolidone K30 as a binder to form a soft mass, granulate through a 20-mesh sieve, dry the wet granules in a ventilated environment at 50°C, and then granulate the dry granules through an 18-mesh sieve. Add sodium carboxymethyl starch and magnesium stearate and mix thoroughly. Compress the mixture using a rotary tablet press to obtain tablets with a weight of 350 mg, thus obtaining the multi-active synergistic compound tablets of this embodiment.

[0034] In this embodiment, the mass ratio of ergothioneine, disodium PQQ, and urolithin A is 20:6:16.

[0035] Example 3: Preparation of a multi-active synergistic compound composition (granules)

[0036] Weigh out 10 parts by weight of L-ergothioneine, 3 parts by weight of disodium pyrroloquinoline quinone, and 8 parts by weight of urolithin A. Place the three active ingredients in a mixing device and mix for 20 minutes at 50 rpm under argon protection to obtain the active ingredient premix.

[0037] Weigh out 45 parts mannitol, 25 parts sucrose, 2 parts hydroxypropyl methylcellulose, 0.5 parts steviol glycosides, and 0.5 parts lemon flavoring as excipients. Mix the premix of active ingredients with mannitol and sucrose evenly, add an aqueous solution of hydroxypropyl methylcellulose to form a soft mass, granulate through a 14-mesh sieve, dry the wet granules at 55°C, and granulate the dry granules through a 12-mesh sieve. Add steviol glycosides and lemon flavoring and mix evenly. Package into 2g bags to obtain the multi-active synergistic compound granule formulation of this embodiment.

[0038] In this embodiment, the mass ratio of ergothioneine, disodium PQQ, and urolithin A is 10:3:8.

[0039] The active ingredient ratios of each embodiment and comparative example are summarized in the table below:

[0040] Comparative Example 1: Algerthion Composition

[0041] Weigh out 32 parts by weight of L-ergothioneine, mix it with 50 parts of microcrystalline cellulose, 15 parts of lactose, and 1 part of magnesium stearate, and fill into capsules according to the process of Example 1, with each capsule containing 300 mg. This comparative example contains only ergothioneine as the active ingredient and does not contain PQQ or urolithin A.

[0042] Comparative Example 2: Single PQQ Composition

[0043] Weigh 10 parts by weight of disodium pyrroloquinoline quinone and mix it with 65 parts of microcrystalline cellulose, 20 parts of lactose, and 1 part of magnesium stearate. Fill capsules according to the process in Example 1, with each capsule containing 300 mg. This comparative example contains only one active ingredient, PQQ.

[0044] Comparative Example 3: Single Urolithin A Composition

[0045] Weigh 25 parts of urolithin A according to the specified weight, mix it with 55 parts of microcrystalline cellulose, 18 parts of lactose, and 1 part of magnesium stearate, and fill into capsules according to the process of Example 1, with each capsule containing 300 mg. This comparative example contains only urolithin A as the active ingredient.

[0046] Comparative Example 4: Ergothioneine and PQQ binary composition

[0047] Weigh out 15 parts by weight of L-ergothione and 5 parts by weight of disodium pyrroloquinoline quinone, mix with 45 parts by weight of microcrystalline cellulose, 25 parts by weight of lactose, 5 parts by weight of crospovidone, and 1 part by weight of magnesium stearate, and fill into capsules according to the process of Example 1, with each capsule containing 300 mg. This comparative example contains two active ingredients, ergothione and PQQ, but does not contain urolithiasis A.

[0048] Comparative Example 5: Ergothioneine and Urolithin A Binary Composition

[0049] Weigh out 15 parts by weight of L-ergothioneine and 12 parts by weight of urolithin A, mix them with 45 parts by weight of microcrystalline cellulose, 22 parts by weight of lactose, 5 parts by weight of crospovidone, and 1 part by weight of magnesium stearate, and fill into capsules according to the process of Example 1, with each capsule containing 300 mg. This comparative example contains two active ingredients, ergothioneine and urolithin A, but does not contain PQQ.

[0050] Comparative Example 6: A binary composition of PQQ and urolithin A

[0051] Weigh out 5 parts by weight of disodium pyrroloquinoline quinone and 12 parts by weight of urolithin A, mix them with 50 parts by weight of microcrystalline cellulose, 27 parts by weight of lactose, 5 parts by weight of crospovidone, and 1 part by weight of magnesium stearate, and fill into capsules according to the process of Example 1, with each capsule containing 300 mg. This comparative example contains two active ingredients, PQQ and urolithin A, but does not contain ergothioneine.

[0052] Comparative Example 7: Ternary composition with proportions outside the range

[0053] Weigh out 40 parts by weight of L-ergothioneine, 2 parts by weight of disodium pyrroloquinoline quinone, and 3 parts by weight of urolithin A. Mix these with 35 parts by weight of microcrystalline cellulose, 17 parts by weight of lactose, 5 parts by weight of crospovidone, and 1 part by weight of magnesium stearate. Fill capsules according to the process of Example 1, with each capsule containing 300 mg. Although this comparative example contains three active ingredients, the proportion of ergothioneine is too high, and the proportions of PQQ and urolithin A are too low. The mass ratio of the three ingredients, 40:2:3, exceeds the range of 5-30:1-10:5-25 defined in claim 1.

[0054] Experimental Example 1: Detection of Mitochondrial Function at the Cellular Level

[0055] HepG2 cells in logarithmic growth phase were seeded at a density of 5 × 10^4 cells per well in 6-well plates. After culturing for 24 hours, the composition of Example 1 (final concentration of 50 μg / mL based on total active ingredient) and the comparative compositions (final concentration of active ingredient consistent with the corresponding component concentration in Example 1) were added. A blank control group (culture medium only) was also set up. After culturing for another 48 hours, the following assays were performed: (1) Mitochondrial membrane potential detection: The ratio of fluorescence intensity of JC-1 polymer (red fluorescence) to monomer (green fluorescence) was detected by flow cytometry using the JC-1 fluorescent probe method. The higher the ratio, the higher the mitochondrial membrane potential and the better the mitochondrial function.

[0056] (2) Detection of intracellular ATP content: The intracellular ATP content was determined by chemiluminescence method using an ATP detection kit, and the relative value was calculated with the blank control group as 100%.

[0057] The expected detection results are as follows (the following data are based on the expected results of the three mechanisms of action and are subject to experimental verification).

[0058] As can be seen from the above design expectations, the ternary composition of Example 1 is superior to both the single-component groups and the binary combination group in terms of mitochondrial membrane potential and ATP content, and is also superior to Comparative Example 7, which has a proportion that exceeds the range. The intracellular ATP content detection results of each group are compared as follows: Figure 4 As shown, the three active ingredients defined in this invention can produce a synergistic effect within a specific mass ratio range, which is beneficial for improving mitochondrial function. The above data represents the design expectation; it is recommended to supplement with actual measured data before formal submission.

[0059] Experiment Example 2: Anti-fatigue experiment in mice

[0060] Sixty SPF-grade male ICR mice, weighing 18–22 g, were randomly divided into 6 groups of 10 mice each: a blank control group (administered via gavage with physiological saline), Example 1 group (administered via gavage with the composition of Example 1, at a dose of 200 mg / kg body weight based on the total amount of active ingredients), Comparative Example 1 group (ergothioneine only, at a dose of 200 mg / kg), Comparative Example 4 group (EGT+PQQ binary, at a dose of 200 mg / kg), Comparative Example 6 group (PQQ+UA binary, at a dose of 200 mg / kg), and Comparative Example 7 group (a ternary compound exceeding the range, at a dose of 200 mg / kg). The mice were administered the saline solution via gavage for 30 consecutive days. Thirty minutes after the last gavage, a weighted swimming test was conducted: mice were placed in a swimming tank with a lead wire bearing 5% of their body weight loaded on their tails, at a water depth of 30 cm and a water temperature of 25 ± 1 °C. The swimming time from entry into the water to exhaustion (head submerged for 10 seconds and unable to resurface) was recorded.

[0061] The expected swimming times for each group of mice under load are as follows (the following data are expected and are subject to experimental verification).

[0062] The expected results from the above design show that the weight-bearing swimming time of mice in Example 1 was significantly longer than that of the blank control group and each comparative group, indicating that the ternary composition of the present invention can enhance the anti-fatigue ability of mice, which is consistent with its mechanism of action of improving mitochondrial function and increasing energy metabolism efficiency. The above data are the expected results; it is recommended to supplement with actual measured data before formal submission.

[0063] Example 4: Preparation of a multi-active synergistic compound composition (oral liquid)

[0064] Weigh out 8 parts by weight of L-ergothioneine, 2 parts by weight of disodium pyrroloquinoline quinone, and 6 parts by weight of urolithin A. Mix the three active ingredients thoroughly under nitrogen protection to obtain the active ingredient premix.

[0065] Weigh out 80 parts purified water, 3 parts xylitol, 0.3 parts citric acid, 0.2 parts sodium citrate, and 0.1 parts potassium sorbate as excipients. Dissolve xylitol, citric acid, sodium citrate, and potassium sorbate in purified water, stir to dissolve, then add the active ingredient premix and stir until completely dissolved or uniformly dispersed. Filter through a 0.22 μm microporous membrane, fill the filtrate into 10 mL oral liquid bottles, seal, and sterilize with flowing steam at 100°C for 20 minutes to obtain the multi-active synergistic compound oral liquid of this embodiment.

[0066] In this embodiment, the mass ratio of ergothioneine, disodium PQQ, and urolithin A is 8:2:6, which falls within the range defined in claim 1.

[0067] Example 5: Preparation of a multi-active synergistic compound composition (powder)

[0068] Weigh out 25 parts by weight of L-ergothioneine, 8 parts by weight of disodium pyrroloquinoline quinone, and 20 parts by weight of urolithin A. Mix the three active ingredients at 60 rpm for 15 minutes under nitrogen protection to obtain an active ingredient premix. Weigh out 35 parts by weight of mannitol, 0.5 parts by weight of steviol glycosides, and 0.5 parts by weight of edible flavoring, mix them evenly with the active ingredient premix, sieve through a 100-mesh sieve, and package into 1.5g packets to obtain the powder of this embodiment.

[0069] In this embodiment, the mass ratio of ergothioneine, disodium PQQ, and urolithin A is 25:8:20.

[0070] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any person skilled in the art can easily conceive of various variations or substitutions within the technical scope disclosed in the present invention, and these should all be included within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.

Claims

1. A multi-active synergistic compound composition, characterized in that, The active ingredient of the composition consists only of ergothioneine, pyrrolquinone or a pharmaceutically acceptable salt thereof, and urolithin A; by weight, the ergothioneine is 5 to 30 parts, the pyrrolquinone or a pharmaceutically acceptable salt thereof is 1 to 10 parts, and the urolithin A is 5 to 25 parts.

2. The multi-active synergistic compound composition according to claim 1, characterized in that, The ergothione is 10-25 parts by weight, the pyrroloquinoline quinone or its pharmaceutically acceptable salt is 2-8 parts, and the urolithin A is 8-20 parts.

3. The multi-active synergistic compound composition according to claim 2, characterized in that, By weight, the ergothione is 12-20 parts, the pyrroloquinoline quinone or its pharmaceutically acceptable salt is 3-6 parts, and the urolithin A is 10-16 parts.

4. The multi-active synergistic compound composition according to claim 1, characterized in that, The pharmaceutically acceptable salt of the pyrroloquinoline quinone is the disodium salt of pyrroloquinoline quinone.

5. The multi-active synergistic compound composition according to claim 1, characterized in that, The ergothioneine is L-ergothioneine.

6. The multi-active synergistic compound composition according to claim 1, characterized in that, The composition further comprises pharmaceutically or food-acceptable excipients, including at least one of fillers, binders, disintegrants, lubricants, flow aids, flavoring agents, and preservatives.

7. The multi-active synergistic compound composition according to claim 6, characterized in that, The composition is in the form of an oral preparation, which includes tablets, hard capsules, granules, powders, or oral liquids.

8. The method for preparing the multi-active synergistic compound composition according to any one of claims 1 to 7, characterized in that, The process includes the following steps: weighing ergothioneine, pyrroloquinoline quinone or their pharmaceutically acceptable salts, and urolithin A according to predetermined mass parts; placing the three in a mixing device and mixing them at a speed of 20-60 rpm for 15-40 minutes under inert gas protection to obtain an active ingredient premix; mixing the active ingredient premix with pharmaceutically or food-acceptable excipients until uniform, and then granulating or directly filling to obtain the multi-active synergistic compound composition.

9. The use of the multi-active synergistic compound composition according to any one of claims 1 to 7 in the preparation of products having the effect of improving mitochondrial function.

10. The application according to claim 9, characterized in that, The improvement of mitochondrial function includes at least one of increasing mitochondrial membrane potential, increasing intracellular ATP content, promoting mitochondrial biogenesis, and inducing mitophagy; the product is a health food, a special medical purpose formula food, or a dietary supplement.

Images